Evidence underlying the clinical management of diabetic macular oedema

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.
Original languageEnglish
Pages (from-to)353-357
Number of pages5
JournalClinical medicine (London, England)
Volume13
Issue number4
DOIs
Publication statusPublished - 01 Aug 2013

Fingerprint

Macular Edema
Diabetic Retinopathy
ruboxistaurin
Fibric Acids
Thiazolidinediones
Angiotensin-Converting Enzyme Inhibitors
Vascular Endothelial Growth Factor A
Blood Glucose
Lasers
Stem Cells
Therapeutics
Blood Pressure
Pharmaceutical Preparations

Cite this

@article{f762d933842140f0a553469f857b654a,
title = "Evidence underlying the clinical management of diabetic macular oedema",
abstract = "Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.",
author = "M.A. Williams and U. Chakravarthy and Michael Williams",
year = "2013",
month = "8",
day = "1",
doi = "10.7861/clinmedicine.13-4-353",
language = "English",
volume = "13",
pages = "353--357",
journal = "Clinical medicine (London, England)",
issn = "1470-2118",
publisher = "Royal College of Physicians",
number = "4",

}

TY - JOUR

T1 - Evidence underlying the clinical management of diabetic macular oedema

AU - Williams, M.A.

AU - Chakravarthy, U.

AU - Williams, Michael

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.

AB - Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84884528593&partnerID=8YFLogxK

U2 - 10.7861/clinmedicine.13-4-353

DO - 10.7861/clinmedicine.13-4-353

M3 - Article

AN - SCOPUS:84884528593

VL - 13

SP - 353

EP - 357

JO - Clinical medicine (London, England)

JF - Clinical medicine (London, England)

SN - 1470-2118

IS - 4

ER -